Molecular diagnostics plays a very important role within the identification of diseases and has gained more public & healthcare specialist attention than ever before. The molecular diagnostics could be a technique used for the molecular biological detection of any change within the structure or expression of a patient's genetic material. consistent with Renub Research, China Molecular Diagnostics Market is expected to be US$ 6.3 Billion by 2026.
Consistent with the WHO, the average prevalence rate of hospital-acquired infections in 2019 was 4.5% and 7.1% within the U.S. and Europe, respectively. Molecular diagnostics play a necessary role within the testing of diseases as they provide quick and effective results. Thus, the growing prevalence of hospital-acquired infections and infectious are further estimated to drive the demand for molecular diagnostics over the forecast period.
Growing funding by Gov. and Organizations for R&D in molecular diagnostics is anticipated to drive the demand for molecular testing. Funding plays a major role within the development process. as an example , Accelerate Diagnostics received USD 19.5 million from various entities, like Oracle Partners, Oracle Institutional Partners, and therefore the Schuler Family Foundation, to enhance the event and sales of communicable disease in vitro diagnostics tests and tools.
The regulatory framework for approvals has always posed major restrictive factors on pharmaceutical, biotechnology, and medical technology industries. Faulty diagnostic kits could provide inaccurate results. Hence, the likelihood of causing harm to the patients has driven the FDA to make sure compliance with premarketing regulations.
Some past years, Molecular diagnostics has changed the face of clinical laboratories by offering easy to use automated molecular systems that provide rapid results with less hands-on time. However, huddles for China diagnostic companies are Lack of government Support, Public Awareness for Molecular Diagnostics test.
COVID-19 effect on Molecular Diagnostics Industry
Besides, COVID-19 has worked as a catalyst for molecular diagnostics industry in China. so as to spread the disease government of China is doing massive number of COVID test. the categories of tests which are done to indentify the coronavirus disease are RT-PCR, and rapid anti-body tests also called serological tests. RT-PCR is taken into account the ‘gold standard’ frontline test. during this test testing is completed by taking a nasal/throat swab from a patient. This test involves extracting ribonucleic acid or RNA, which is that the genetic material of the virus. this is often a reasonably expensive test it requires RNA extracting machines, a laboratory and trained technicians. On the opposite hand rapid anti-body tests are portable, administered on-site, provide quick answers and are inexpensive too.
China molecular diagnostics market is segmented into three main categories: Oncology Test, infectious disease Test and genetic disorder Test. Further, Oncology Test has been segmented into three types: glandular cancer, Colorectal Cancer and breast cancer. communicable disease Test has been further categorized into two main types, which is virology and HPV. Genetic Test has been categorized into HLA and Blood Screening. Blood screening test may be a dominating segment within the China molecular genetic testing market. consistent with Renub Research analysis nearly 441 million molecular diagnostic tests are going to be performed in China by the top of 2026 of which Virology accounts for one among the most performed tests segments.
DICON Clinical Laboratories, Zhejiang Di’an Diagnostics Technology Co., Ltd, Kindstar Global, BGI-Shenzhen, A, Guangzhou Kingmed Diagnostics Center Co. Ltd and OriGene Technologies holds majority of market share in China. However, restriction on export is expected to possess minimal impact on the manufacturers because the demand is extremely high in China which is creating a strong revenue pool for manufacturers dealing within the molecular diagnostics sector.
Renub Research report titled “China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA)]” provides a complete analysis of China Molecular Diagnostics Market.
By Application
The report studies the market and volume of the following segments in Molecular Diagnostics: Infectious Disease Testing (Virology, HPV), Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), and Genetic Disease Testing (Blood Screening, HLA).
Request a free Sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-molecular-diagnostics-market-test-volume-and-forecast-491-p.php
Segment Covered in this report are as follows:
Oncology Testing Market and Volume
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
Infectious Disease Testing Market and Volume
• Virology
• HPV
Genetic Testing Market and Volume
• Blood Screening
• HLA
Profiles of Private Clinical Labs and Diagnostic Services Companies in China
• Zhejiang Di’an Diagnostics Technology Co., Ltd
• ADICON Clinical Laboratories
• Guangzhou Kingmed Diagnostics Center Co. Ltd.
• Kindstar Global (Privately held)
• BGI-Shenzhen (Privately held)
• OriGene Technologies (Privately held)
Industry Related Opportunity:
Japan In Vitro Diagnostics (IVD) Market: https://www.renub.com/japan-in-vitro-diagnostics-market-p.php
Global Molecular Diagnostics Market: https://www.renub.com/global-molecular-diagnostics-market-and-future-forecast-2010-2014-334-p.php
About Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research
0 Comments